Outsourced products
Menactra Inj.
- ClassificationPrescription Drug
- Therapeutics classificationMENINGOCOCCAL VACCINES (MENINGOCOCCUS A,C,Y,W-135, TETRAVALENT PURIFIED POLYSACCHARIDES ANTIGEN CONJUGATED)
- ManufacturerSanofi-Aventis Korea
A clear to slightly turbid liquid supplied in a vial
Meningococcal Serogroup A Polysaccharide C. diphtheriae Conjugate 4 μg, Meningococcal Serogroup C Polysaccharide C. diphtheriae Conjugate 4 μg, Meningococcal Serogroup Y Polysaccharide C. diphtheriae Conjugate 4 μg, Meningococcal Serogroup W-135 Polysaccharide C. diphtheriae Conjugate 4 μg in one vial (0.5mL)
Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135, and Y in individuals 9 months through 55 years of age
1. Method of Administration
Administer intramuscularly. Never administer intravenously or subcutaneously.
2. Age and Schedule
9 to 23 months of age: 2 doses of 0.5 mL each, given 3 months apart.
2 to 55 years of age: A single dose of 0.5 mL.
1 vial/box [Vial (0.5 mL)]
Store at 2~8℃, avoid freezing.